We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC: Akorn May Acquire VersaPharm, if it Unloads Generic Rifampin Rights
FTC: Akorn May Acquire VersaPharm, if it Unloads Generic Rifampin Rights
Generics manufacturer Akorn must sell its rights to a pending ANDA for the tuberculosis drug rifampin before it can complete its $324 million acquisition of VersaPharm, the Federal Trade Commission said.